Eli Lilly Pitches New Alzheimer's Drug to the FDA

Yesterday, Eli Lilly asked the Food and Drug Administration to fast-track its new Alzheimer's drug,  donanemab. According to an article published online by The Motley Fool, "Lilly is seeking the go-ahead via the controversial "accelerated approval" process, which only requires proof that it is "reasonably likely" to help." Read more about it here: fool.com/donanemab.

If approved, donanemab will only be the second drug in 18 years approved to treat Alzheimer's disease. Biogen's Aducanumab was approved this past June. 

memory-care

For more information about we support people living with Alzheimer's disease and other forms of dementia, contact us at 440-294-1500 (Cleveland) or 614-356-9810 (Columbus).